BioRestorative Therapies, Inc. Price & Performance (BRTX)

Pfizer has announced the discontinuation of its gene therapy, fidanacogene elaparvovec (Beqvez), for hemophilia B. Despite being FDA-approved, the decision reflects challenges in the gene therapy market, where uptake for non-oncology treatments remains slow. This move underscores the complexities of commercializing advanced therapies in niche medical fields.1

BioRestorative Therapies has received FDA Fast Track designation for its stem cell therapy, BRTX-100, targeting chronic lumbar disc disease. This milestone highlights the unmet need for alternatives to opioids and surgeries, promising expedited development and approval processes for the therapy, which has shown positive Phase 2 results.2

bluebird bio has agreed to be acquired by Carlyle and SK Capital. The deal aims to provide financial stability to support its gene therapy products for genetic disorders, including sickle cell disease. The acquisition reflects the challenges smaller biotech firms face in sustaining operations while advancing innovative treatments.1